Related Experiment Video
Updated: Jul 15, 2025

06:17
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
12.0K
Disrupting Dimeric β-Amyloid by Electric Fields.
Pablo Andrés Vargas-Rosales1, Alessio D'Addio1, Yang Zhang1
1Department of Biochemistry, University of Zurich, CH-8057 Zürich, Switzerland.
ACS Physical Chemistry Au
|October 2, 2023
Summary
Investigating amyloid beta dimers, researchers found that oscillating electric fields can disrupt these toxic Alzheimer's disease oligomers. This disruption, observed via molecular dynamics, suggests a potential new therapeutic avenue.
Area of Science:
- Biophysics
- Neuroscience
- Computational Chemistry
Background:
- Early oligomers of amyloid beta (Aβ) peptides are linked to Alzheimer's disease pathogenesis.
- The transient nature of these Aβ oligomers hinders structural characterization and understanding of their toxicity.
- Minimal toxic species, such as β-amyloid dimers, are key targets for therapeutic intervention.
Purpose of the Study:
- To investigate the structural stability of Aβ42 dimers under oscillating electric fields.
- To explore the potential of electric fields in disrupting toxic amyloid oligomers.
Main Methods:
- Utilized deep learning (AlphaFold-multimer) to generate initial models of Aβ42 dimers.
- Employed molecular dynamics (MD) simulations to analyze dimer flexibility and secondary structure.
- Conducted MD simulations with an external oscillating electric field (1 GHz) to assess stability.
Main Results:
- Structurally stable Aβ42 dimer models were identified, consistent with microsecond-long MD sampling.
- High-strength oscillating electric fields induced a rapid decay of β-sheet content in Aβ42 dimers.
- Aβ42 dimers exhibited lower structural stability compared to helical leucine zipper peptide dimers under electric fields.
Conclusions:
- External oscillating electric fields can disrupt the structure of amyloid oligomers.
- This finding suggests a potential novel approach for targeting Alzheimer's disease pathology.
- Further experimental validation using brain organoids and in vivo studies is warranted.

